Screener
Taysha Gene Therapies, Inc. TSHA Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-207666
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Purchase of research and development license | (3,000) | — |
| Purchase of property, plant and equipment | (24) | (378) |
| Other | — | 7 |
| Net cash used in investing activities | (3,024) | (371) |
| Cash flows from financing activities | ||
| Payment of shelf registration costs | — | (47) |
| Proceeds from common stock issuances under ESPP | 176 | 75 |
| Proceeds from stock option exercises | 516 | — |
Item 1. Financial Statements.
FAQ
- What is Taysha Gene Therapies, Inc.'s investing cash flow?
- Taysha Gene Therapies, Inc. (TSHA) reported investing cash flow of -$3.02M in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s investing cash flow changed year-over-year?
- Taysha Gene Therapies, Inc.'s investing cash flow decreased by 715.1% year-over-year, from -$371K to -$3.02M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s investing cash flow?
- Over 3 years (2021 to 2024), Taysha Gene Therapies, Inc.'s investing cash flow has grown at a -74.1% compound annual growth rate (CAGR), from -$21.55M to -$376K.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Taysha Gene Therapies, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude